RU2014117558A - Лечение ожирения и нарушений, связанных с ожирением, путем нацеливания фармакологических агентов на калиевые каналы - Google Patents
Лечение ожирения и нарушений, связанных с ожирением, путем нацеливания фармакологических агентов на калиевые каналы Download PDFInfo
- Publication number
- RU2014117558A RU2014117558A RU2014117558/15A RU2014117558A RU2014117558A RU 2014117558 A RU2014117558 A RU 2014117558A RU 2014117558/15 A RU2014117558/15 A RU 2014117558/15A RU 2014117558 A RU2014117558 A RU 2014117558A RU 2014117558 A RU2014117558 A RU 2014117558A
- Authority
- RU
- Russia
- Prior art keywords
- aeeac
- chemical compound
- shk toxin
- pmp
- compound attached
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract 8
- 235000020824 obesity Nutrition 0.000 title claims abstract 8
- 102000004257 Potassium Channel Human genes 0.000 title claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 4
- 108020001213 potassium channel Proteins 0.000 title claims abstract 4
- 239000002831 pharmacologic agent Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 239000003053 toxin Substances 0.000 claims abstract 48
- 231100000765 toxin Toxicity 0.000 claims abstract 48
- 150000001875 compounds Chemical class 0.000 claims abstract 40
- 239000003795 chemical substances by application Substances 0.000 claims abstract 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 3
- 241001465754 Metazoa Species 0.000 claims abstract 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims abstract 3
- 230000003213 activating effect Effects 0.000 claims abstract 3
- 210000003486 adipose tissue brown Anatomy 0.000 claims abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542751P | 2011-10-03 | 2011-10-03 | |
| US61/542,751 | 2011-10-03 | ||
| PCT/US2012/058495 WO2013052507A1 (en) | 2011-10-03 | 2012-10-02 | TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014117558A true RU2014117558A (ru) | 2015-11-10 |
Family
ID=48044112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014117558/15A RU2014117558A (ru) | 2011-10-03 | 2012-10-02 | Лечение ожирения и нарушений, связанных с ожирением, путем нацеливания фармакологических агентов на калиевые каналы |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150072940A1 (enExample) |
| EP (1) | EP2763702A4 (enExample) |
| JP (1) | JP2014531469A (enExample) |
| KR (1) | KR20140108518A (enExample) |
| CN (1) | CN103987408A (enExample) |
| AU (1) | AU2012318736A1 (enExample) |
| BR (1) | BR112014008065A2 (enExample) |
| CA (1) | CA2850357A1 (enExample) |
| HK (1) | HK1201048A1 (enExample) |
| IL (1) | IL231873A0 (enExample) |
| IN (1) | IN2014CN03333A (enExample) |
| MX (1) | MX2014004029A (enExample) |
| RU (1) | RU2014117558A (enExample) |
| SG (1) | SG11201401193XA (enExample) |
| TW (1) | TW201321403A (enExample) |
| WO (1) | WO2013052507A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2474316B1 (en) * | 2004-10-07 | 2016-04-06 | The Regents of The University of California | Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels |
| SG10201604468QA (en) | 2011-06-06 | 2016-07-28 | Kineta One Llc | Shk-based pharmaceutical compositions and methods of manufacturing and using the same |
| JP2014531469A (ja) | 2011-10-03 | 2014-11-27 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カ | Ｋｖ１．３カリウムチャネルの薬理学的標的化による肥満症および肥満症関連障害の治療 |
| US10265384B2 (en) * | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
| TWI698438B (zh) | 2015-03-13 | 2020-07-11 | 德商４Ｓｃ製藥公司 | Ｋv１.３抑制劑及其醫學應用 |
| TWI701249B (zh) | 2015-03-13 | 2020-08-11 | 德商４Ｓｃ製藥公司 | Ｋv１.３抑制劑及其醫學應用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453270A (en) | 1992-03-30 | 1995-09-26 | Hypermetabolic Therapies, Inc. | Pharmaceutical composition and method for hypermetabolic weight loss |
| US6077680A (en) * | 1996-11-27 | 2000-06-20 | The University Of Florida | ShK toxin compositions and methods of use |
| AU8052798A (en) * | 1997-09-17 | 1999-04-05 | Bachem Bioscience, Inc. | Polypeptide compositions that inhibit potassium channel activity and uses herefor |
| JP3207823B2 (ja) | 1999-04-28 | 2001-09-10 | リノール油脂株式会社 | 共役リノール酸を有効成分とする褐色脂肪増加剤 |
| US6616944B2 (en) | 2000-03-08 | 2003-09-09 | Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh | Self-assembling colloidal carriers for protein delivery |
| US6861405B2 (en) * | 2001-06-12 | 2005-03-01 | Yale University | Compositions and methods relating to glucose metabolism, weight control, and food intake |
| EP2474316B1 (en) * | 2004-10-07 | 2016-04-06 | The Regents of The University of California | Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| AU2006281368A1 (en) * | 2005-08-17 | 2007-02-22 | Solvay Pharmaceuticals Gmbh | Method of using potassium channel inhibiting compounds |
| AR074558A1 (es) * | 2008-12-12 | 2011-01-26 | Solvay Pharm Bv | Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3 |
| JP2014531469A (ja) | 2011-10-03 | 2014-11-27 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カ | Ｋｖ１．３カリウムチャネルの薬理学的標的化による肥満症および肥満症関連障害の治療 |
-
2012
- 2012-10-02 JP JP2014534641A patent/JP2014531469A/ja active Pending
- 2012-10-02 BR BR112014008065A patent/BR112014008065A2/pt not_active IP Right Cessation
- 2012-10-02 IN IN3333CHN2014 patent/IN2014CN03333A/en unknown
- 2012-10-02 US US14/347,602 patent/US20150072940A1/en not_active Abandoned
- 2012-10-02 EP EP12838795.8A patent/EP2763702A4/en not_active Withdrawn
- 2012-10-02 SG SG11201401193XA patent/SG11201401193XA/en unknown
- 2012-10-02 MX MX2014004029A patent/MX2014004029A/es unknown
- 2012-10-02 KR KR1020147012093A patent/KR20140108518A/ko not_active Withdrawn
- 2012-10-02 CN CN201280049696.6A patent/CN103987408A/zh active Pending
- 2012-10-02 WO PCT/US2012/058495 patent/WO2013052507A1/en not_active Ceased
- 2012-10-02 RU RU2014117558/15A patent/RU2014117558A/ru not_active Application Discontinuation
- 2012-10-02 HK HK15101586.1A patent/HK1201048A1/xx unknown
- 2012-10-02 CA CA2850357A patent/CA2850357A1/en not_active Abandoned
- 2012-10-02 AU AU2012318736A patent/AU2012318736A1/en not_active Abandoned
- 2012-10-03 TW TW101136560A patent/TW201321403A/zh unknown
-
2014
- 2014-04-02 IL IL231873A patent/IL231873A0/en unknown
-
2016
- 2016-02-22 US US15/049,353 patent/US9878006B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IN2014CN03333A (enExample) | 2015-07-03 |
| US20150072940A1 (en) | 2015-03-12 |
| US20170095530A1 (en) | 2017-04-06 |
| SG11201401193XA (en) | 2014-05-29 |
| AU2012318736A1 (en) | 2014-05-22 |
| BR112014008065A2 (pt) | 2019-09-24 |
| JP2014531469A (ja) | 2014-11-27 |
| WO2013052507A1 (en) | 2013-04-11 |
| KR20140108518A (ko) | 2014-09-11 |
| CA2850357A1 (en) | 2013-04-11 |
| MX2014004029A (es) | 2014-08-01 |
| CN103987408A (zh) | 2014-08-13 |
| IL231873A0 (en) | 2014-05-28 |
| HK1201048A1 (en) | 2015-08-21 |
| TW201321403A (zh) | 2013-06-01 |
| EP2763702A1 (en) | 2014-08-13 |
| EP2763702A4 (en) | 2015-04-15 |
| US9878006B2 (en) | 2018-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014117558A (ru) | Лечение ожирения и нарушений, связанных с ожирением, путем нацеливания фармакологических агентов на калиевые каналы | |
| PH12013500826A1 (en) | Means and methods for treating dlbcl | |
| BR112014009418A2 (pt) | macrociclos peptidomiméticos | |
| SG163525A1 (en) | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation | |
| UY35340A (es) | Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123 | |
| MX2015013749A (es) | Metodos para aumentar la sintesis de proteinas musculares despues de entrenamiento simultáneo. | |
| CL2012000702A1 (es) | Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson. | |
| CL2007003622A1 (es) | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. | |
| EA201391604A1 (ru) | Способ лечения рака и раковой боли в костях | |
| GT201200096A (es) | Anticuerpos monoclonales | |
| PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
| UA94899C2 (ru) | Фиксированное дозирование антител к her | |
| NZ590127A (en) | Notch1 receptor binding agents and methods of use thereof | |
| UA109658C2 (xx) | Антитіло проти cgrp | |
| MX355543B (es) | Macrociclos peptidomiméticos. | |
| EA201491605A1 (ru) | Способы улучшения функции диафрагмы | |
| MY160041A (en) | Compositions and methods for treating parasitic infections | |
| GB2497475A (en) | Kits, components and methods for tissue reconstruction | |
| EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
| NZ601588A (en) | Methods for treating breast cancer | |
| EA201291195A1 (ru) | Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1 | |
| NI201300038A (es) | Composiciones y métodos para el tratamiento de la mielofibrosis | |
| NZ603196A (en) | Methods of use of soluble cd24 for therapy of rheumatoid arthritis | |
| BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
| BR112014009785A8 (pt) | método para tratar ou reduzir efp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20151005 |